Capricor Therapeutics Inc.
CAPR | NASDAQ
$9.35
+$0.45 (+5.06%)
Sep 22, 2026, 2:48 PM ET · Market open
Company Profile
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Key Executives
| Name | Position |
|---|---|
| Linda Marbán | Co-Founder, President, Chief Executive Officer & Director |
| Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer |
| Frank Isaac Litvack FACC | Executive Chairman of the Board |
| Karen G. Krasney | Executive Vice President, General Counsel & Secretary |
| Kristi A. H. Elliott | Chief Operating & Science Officer |
| Mark Awadalla | Chief Development Officer |
| Michael Maurer | Chief Commercial Officer |
| Micheal Binks | Chief Medical Officer |
| Minghao Sun | Senior Vice President of Quality Control, Research & Product Development |
| Nathaniel Hogan | Director of Biostatistics of Capricor Therapeutics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 24, 2026 | 8-K | Current Report |
| Aug 19, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 03, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 29, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 8-K | Current Report |
Capricor Therapeutics Inc.
| Country | United States |
| IPO Date | Feb 12, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 231 |
| CEO | Linda Marbán |
Contact Details
10865 Road to the Cure San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | CAPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133869 |
| CUSIP Number | 14070B309 |
| ISIN Number | US14070B3096 |
| SIC Code | 2834 |
Recent News
- 2 months ago / businesswire.comRosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR
- 2 months ago / businesswire.comSecurities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
- 2 months ago / globenewswire.comCapricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
- 2 months ago / globenewswire.comCAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC
- 2 months ago / benzinga.comCapricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data
- 2 months ago / benzinga.comQUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli
- 2 months ago / globenewswire.comCapricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
- 2 months ago / proactiveinvestors.comCapricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy
- 2 months ago / benzinga.comCapricor Therapeutics Stock Plunges After FDA Releases Briefing Documents
- 2 months ago / reuters.comFDA staff flags concerns for Capricor's Duchenne heart disease therapy
Add to Watchlist
Select watchlists to add or remove CAPR